Haleon (HLN) Stock Forecast, Price Target & Predictions
HLN Stock Forecast
Haleon stock forecast is as follows: an average price target of $9.15 (represents a -5.67% downside from HLN’s last price of $9.70) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HLN Price Target
The average price target for Haleon (HLN) is $9.15 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $9.15 to $9.15. This represents a potential -5.67% downside from HLN's last price of $9.70.
HLN Analyst Ratings
According to 7 Wall Street analysts, Haleon's rating consensus is 'Buy'. The analyst rating breakdown for HLN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haleon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 08, 2024 | Rashad Kawan | Morgan Stanley | $9.15 | $8.29 | 10.37% | -5.67% |
The latest Haleon stock forecast, released on Apr 08, 2024 by Rashad Kawan from Morgan Stanley, set a price target of $9.15, which represents a 10.37% increase from the stock price at the time of the forecast ($8.29), and a -5.67% decrease from HLN last price ($9.70).
Haleon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.15 |
| Last Closing Price | $9.70 | $9.70 | $9.70 |
| Upside/Downside | -100.00% | -100.00% | -5.67% |
In the current month, the average price target of Haleon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Haleon's last price of $9.70. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Sep 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 06, 2024 | Goldman Sachs | Neutral | Downgrade | |
| Aug 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 01, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 09, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 09, 2024 | Barclays | Overweight | Overweight | Hold |
| May 02, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 17, 2024 | HSBC | Buy | Initialise | |
| Apr 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 21, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
Haleon's last stock rating was published by Deutsche Bank on Oct 08, 2024. The company gave HLN a "Hold" rating, the same as its previous rate.
Haleon Financial Forecast
Haleon Revenue Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.99B | $3.79B |
| Avg Forecast | $7.08B | $7.06B | $3.29B | $6.80B | $3.08B | $2.79B | $3.70B | $7.03B | $7.06B | $3.29B | $3.19B | $3.08B |
| High Forecast | $12.86B | $12.84B | $5.98B | $12.35B | $5.60B | $5.06B | $6.72B | $12.79B | $12.84B | $5.98B | $5.80B | $5.60B |
| Low Forecast | $4.14B | $4.14B | $1.93B | $3.98B | $1.80B | $1.63B | $2.17B | $4.12B | $4.14B | $1.93B | $1.87B | $1.80B |
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.23% |
Haleon's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.29B, with a low forecast of $1.93B, and a high forecast of $5.98B. HLN's average Quarter revenue forecast represents a 10.22% increase compared to the company's last Quarter revenue of $2.99B (Mar 23).
Haleon EBITDA Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $637.00M | $619.00M |
| Avg Forecast | $1.38B | $1.37B | $639.88M | $1.32B | $599.03M | $541.54M | $718.82M | $1.37B | $1.37B | $639.88M | $620.51M | $599.03M |
| High Forecast | $2.50B | $2.50B | $1.16B | $2.40B | $1.09B | $984.33M | $1.31B | $2.49B | $2.50B | $1.16B | $1.13B | $1.09B |
| Low Forecast | $805.63M | $804.24M | $374.71M | $773.78M | $350.79M | $317.12M | $420.94M | $800.88M | $804.24M | $374.71M | $363.37M | $350.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% |
1 analysts predict HLN's average Quarter EBITDA for Jun 23 to be $639.88M, with a high of $1.16B and a low of $374.71M. This is 0.45% upper than Haleon's previous annual EBITDA (Mar 23) of $637.00M.
Haleon Net Income Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $389.00M | $198.00M |
| Avg Forecast | $1.63B | $1.59B | $884.58M | $1.69B | $1.53B | $674.18M | $823.56M | $1.69B | $1.66B | $885.95M | $742.01M | $14.24B |
| High Forecast | $3.37B | $3.28B | $1.82B | $3.49B | $3.16B | $679.15M | $1.70B | $3.48B | $3.42B | $1.83B | $1.53B | $29.39B |
| Low Forecast | $753.59M | $734.30M | $408.03M | $780.45M | $706.76M | $669.22M | $379.89M | $779.13M | $765.79M | $408.67M | $342.27M | $6.57B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.52% | 0.01% |
Haleon's average Quarter net income forecast for Jun 23 is $885.95M, with a range of $408.67M to $1.83B. HLN's average Quarter net income forecast represents a 127.75% increase compared to the company's last Quarter net income of $389.00M (Mar 23).
Haleon SG&A Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $1.14B | $1.51B |
| Avg Forecast | $2.93B | $2.93B | $1.36B | $2.82B | $1.28B | $1.15B | $1.53B | $2.91B | $2.93B | $1.36B | $1.32B | $1.28B |
| High Forecast | $5.33B | $5.32B | $2.48B | $5.12B | $2.32B | $2.10B | $2.78B | $5.30B | $5.32B | $2.48B | $2.40B | $2.32B |
| Low Forecast | $1.72B | $1.71B | $798.31M | $1.65B | $747.35M | $675.61M | $896.79M | $1.71B | $1.71B | $798.31M | $774.14M | $747.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.86% | 1.18% |
Haleon's average Quarter SG&A projection for Jun 23 is $1.36B, based on 1 Wall Street analysts, with a range of $798.31M to $2.48B. The forecast indicates a 20.11% rise compared to HLN last annual SG&A of $1.14B (Mar 23).
Haleon EPS Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.08 | $0.04 |
| Avg Forecast | $0.18 | $0.17 | $0.10 | $0.18 | $0.17 | $0.07 | $0.09 | $0.18 | $0.18 | $0.10 | $0.08 | $1.55 |
| High Forecast | $0.37 | $0.36 | $0.20 | $0.38 | $0.34 | $0.07 | $0.18 | $0.38 | $0.37 | $0.20 | $0.17 | $3.19 |
| Low Forecast | $0.08 | $0.08 | $0.04 | $0.08 | $0.08 | $0.07 | $0.04 | $0.08 | $0.08 | $0.04 | $0.04 | $0.71 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.03% |
According to 1 Wall Street analysts, Haleon's projected average Quarter EPS for Jun 23 is $0.10, with a low estimate of $0.04 and a high estimate of $0.20. This represents a 14.49% increase compared to HLN previous annual EPS of $0.08 (Mar 23).
Haleon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | $8.79 | $51.50 | 485.89% | Buy |
| ESPR | Esperion Therapeutics | $2.46 | $8.00 | 225.20% | Buy |
| LNTH | Lantheus | $92.66 | $155.00 | 67.28% | Buy |
| ELAN | Elanco Animal Health | $12.31 | $17.50 | 42.16% | Buy |
| ZTS | Zoetis | $170.79 | $221.00 | 29.40% | Buy |
| VTRS | Viatris | $12.59 | $15.00 | 19.14% | Hold |
| HCM | HUTCHMED (China) | $14.86 | $17.50 | 17.77% | Buy |
| NBIX | Neurocrine Biosciences | $136.69 | $156.14 | 14.23% | Buy |
| TEVA | Teva Pharmaceutical Industries | $20.88 | $23.20 | 11.11% | Buy |
| BHC | Bausch Health Companies | $7.68 | $8.33 | 8.46% | Hold |
| CTLT | Catalent | $63.48 | $63.50 | 0.03% | Hold |
| HLN | Haleon | $9.91 | $9.15 | -7.67% | Buy |